ReShape Lifesciences (RSLSD) Stock Price, News & Analysis

Company Overview

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 6,500 shs
• Average Volume: 1,362 shs
• Market Capitalization: $1.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RSLSD Stock Analysis - Frequently Asked Questions

How do I buy shares of ReShape Lifesciences?

Shares of RSLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Surgical, Medical, And Dental Instruments And Supplies
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:RSLSD
• CIK: N/A
• Web: www.reshapelifesciences.com
• Phone: 949-429-6680
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$81.15 million
• Net Margins: -668.58%
• Pretax Margin: N/A
• Return on Equity: -163.22%
• Return on Assets: -52.10%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 1.17
• Quick Ratio: 1.07

Sales & Book Value

• Annual Sales: $610,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.08
• Book Value: $341.84 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 354,000
• Free Float: N/A
• Market Cap: $1.90 million
• Optionable: Not Optionable
• Beta: 2.03